Clinical trial
The Combination of Oral Upadacitinib and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
NCT07064889 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Combination of Oral Upadacitinib and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 30, 2025
- Completion date
- December 30, 2027
- Enrollment
- 132 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
immune thrombocytopenia